AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

Obicetrapib monotherapy significantly improved the lipid profile of patients with heterozygous familial hypercholesterolemia ...

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

A designer has created a concept car capable of driving on both water and land. Imagined by Bernardo Pereira, a student at ...

Many cruise passengers don't consider themselves gamblers, yet they often take risks with their cabin choices. In this video, ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

today announced the appointment of Adele Gulfo as an independent AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug prices sent shares of pharmaceuticals companies lower across the ...

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF), already licensed for the treatment of chronic obstructive pulmonary disease ...